Last reviewed · How we verify
RC108
At a glance
| Generic name | RC108 |
|---|---|
| Also known as | Furmonertinib, Toripalimab, RC108 for injection, RC108 For Injection； |
| Sponsor | RemeGen Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (PHASE1)
- A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (PHASE2)
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC (PHASE2)
- RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC (PHASE1, PHASE2)
- Clopidogrel and Aspirin for the Treatment of Polycythemia Vera (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RC108 CI brief — competitive landscape report
- RC108 updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI